Note 31 – Events After the Balance Sheet Date Audited

Lonza Group Ltd has successfully placed 5 million new shares, which were listed and admitted to trading on the SIX Swiss Exchange on 3 February 2017 (see note 4.4).

On 27 February 2017 Lonza announced that it entered into a strategic partnership (in the form of a joint venture) with Sanofi to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. The initial investment will be around CHF 290 million (€ 270 million), to be split equally between each company.

The Consolidated Financial Statements for 2016 were approved for issue by the Board of Directors on 8 March 2017 and are subject to approval by the Annual General Meeting on 25 April 2017.